Journal
ATHEROSCLEROSIS
Volume 229, Issue 2, Pages 415-422Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.atherosclerosis.2013.05.010
Keywords
Simvastatin; Ezetimibe; Correlation; Lipoprotein; Apolipoprotein B
Funding
- Abbott
- AstraZeneca
- Boehringer-Ingelheim
- Genzyme
- Kowa
- Eli Lilly Co.
- Merck Co., Inc.
- Schering-Plough
- Novartis
- Pfizer
- Recordati
- Roche
- sanofi-aventis
- SMB
- Abbott Laboratories
- Genzyme/sanofi aventis
- Amarin
- Regeneron/sanofi-aventis
- GlaxoSmithKline
- Merck
Ask authors/readers for more resources
Background/synopsis: Apolipoprotein (apo) B is highly predictive of coronary risk, especially in patients with high triglycerides (TG). This post hoc analysis evaluated the effects of lipid-lowering therapy on correlations between apoB and low-density lipoprotein cholesterol (apoB: LDL-C) and non-high-density lipoprotein cholesterol (apoB: non-HDL-C) in patients with TG< and >= 200 mg/dL. Methods: This analysis used data from 3 randomized clinical trials in patients with primary hypercholesterolemia receiving placebo, ezetimibe (EZE), simvastatin (SIMVA) or EZE/SIMVA for 12 weeks. Simple linear regression analyses predicted LDL-C and non-HDL-C levels corresponding to apoB values (80 mg/dL) at baseline and Week 12. Results: ApoB correlated with LDL-C (r >= 0.76) and non-HDL-C (r >= 0.86) at baseline. The correlations were strengthened with SIMVA and EZE/SIMVA at Week 12 (r >= 0.88 for LDL-C and r >= 0.94 for non-HDL-C). The predicted LDL-C and non-HDL-C values were lower following treatment with SIMVA or EZE/SIMVA than for placebo and EZE. For SIMVA and EZE/SIMVA, the predicted LDL-C and non-HDL-C values were closer to more aggressive LDL-C and non-HDL-C levels (i.e., 70 and 100 mg/dL, respectively). The apoB: LDL-C and apoB: non-HDL-C correlations were weaker and the predicted LDL-C values were generally lower in high TG patients than in low TG patients both at baseline and Week 12. In contrast, the predicted non-HDL-C values were generally higher in high versus low TG patients at baseline but less so at Week 12. Conclusion: After treatment with EZE, SIMVA, or EZE/SIMVA, a given apoB value corresponds to lower LDL-C and non-HDL-C levels than those obtained from untreated patients. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available